Prasugrel

• VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (VERONICA) Recruiting
  2024-512436-29-00 Phase III/IV 1 country Fundacion Epic
• Safety and efficacy of very short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy in older patients undergoing percutaneou… Recruiting
  2023-507545-28-00 Phase IV 1 country Centre Hospitalier Universitaire De Caen Normandie
• Optimal antiplatelet therapy in patients after coronary artery bypass grafting. Recruiting
  2025-521892-30-00 Phase III 1 country Dolnoslaskie Centrum Chorob Serca Im. Prof. Zbigniewa Religi Medinet Sp. z o.o.
• PROMOTE Recruiting
  2024-520351-24-00 Phase IV 1 country Amsterdam UMC Stichting
• Treatment with a single drug that prevents blood clot formation followed by an anticoagulant drug in patients with irregular heartbeat who h… Recruiting
  2023-509717-36-00 Phase III 7 countries Insel Gruppe AG
• The dosage of antithrombotics adjusted to body weight Recruiting
  2024-518890-33-00 Phase IV 1 country Sint Antonius Ziekenhuis Stichting
• COMPARE STEMI ONE- Comparison Of reduced DAPT followed by P2Y12 inhibitor Monotherapy with Prasugrel vs stAndard Regimen in STEMI patients t… Recruiting
  2024-515883-30-00 Phase IV 5 countries Research Maatschap Cardiologen Rotterdam Zuid
• Drug-Coated Balloon in Anticoagulated and Bleeding Risk Patients Undergoing PCI (DEBATE) Recruiting
  2023-504340-34-01 Phase IV 3 countries Wellbeing Services County Of North Karelia Siun Sote
• Personalized, CT-guided antithrombotic therapy versus lifelong single antiplatelet therapy to reduce thromboembolic and bleeding events in n… Recruiting
  2023-504637-42-01 Phase IV 5 countries St Antonius Hospital
• Early reduction of antiplatelet therapy in patients with Acute Coronary Syndrome treated with stent implantation and at high risk of bleedin… Recruiting
  2023-509868-20-00 Phase III 1 country Azienda Ospedaliera Universitaria Gaetano Martino Messina
• WOEST-3 Recruiting
  2022-502140-13-00 Phase IV 4 countries St Antonius Hospital
• The Dan-DAPT trial Recruiting
  2022-500125-32-00 Phase IV 1 country Rigshospitalet
• Study to evaluate reduced antiplatelet therapy after angiolite stent implantation in patients with coronary artery disease Ended
  2023-507015-35-00 Phase III 3 countries Ivascular S.L.
• The SORT OUT XII DAPT Duration Trial Ended
  2024-515236-69-00 Phase III/IV 1 country Odense University Hospital
• Individualized anti-platelet therapy in patients with stable coronary artery disease undergoing stenting Ended
  2023-504078-39-01 Phase IV 1 country St Antonius Hospital
• A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended
  2022-501418-69-00 Phase III 20 countries Janssen - Cilag International
• Escalated single Platelet Inhibition for one month plus Direct oral anticoagulation in patients with Atrial fibrillation and acUte coRonary … Ended
  2024-512727-36-00 Phase IV 2 countries Klinikum der Universitaet Muenchen AöR
• A study designed to evaluate a modified Anti-Platelet Therapy (drugs that preventblood platelets from clotting) after implantation of a Fire… Ended
  2024-519854-35-00 Phase IV 3 countries SORIN CRM SAS (Microport CRM)

Showing 1–18 of 18 trials